Skip to main content
    R

    Rigel Pharmaceuticals Inc (RIGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $43.73
    -0.73 (-1.64%)

    Market Cap: $837.18M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rigel Pharmaceuticals Inc (RIGL) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Rigel Pharmaceuticals (RIGL) is expected to report earnings on Mar 1, 2027. In the quarter ended Sep 30, 2026, Rigel Pharmaceuticals reported EPS of $0.65, below the $0.87 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    59%(23/39)
    Avg Surprise
    +45.97%

    Upcoming Estimates

    Reports Mar 1, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.94
    Range$0.85 - $1.06
    7 analysts
    Revenue Consensus
    $93.37M
    Range$85.26M - $98.39M
    7 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.52
    Range$0.52 - $0.52
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.57-8.8%
    60d ago$0.57-8.8%
    30d ago$0.57-8.8%
    7d ago$0.57-8.8%
    Current$0.52
    Revenue Consensus
    $77.80M
    Range$70.00M - $85.60M
    2 analysts

    Next Report

    RIGL has an expected report date of Mar 1, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 16.1% below the $1.12 reported for the quarter ended Dec 31, 2025.

    RIGL Earnings Call

    The latest RIGL earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, RIGL beat 23, missed 11 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $80.89M, up 16.5% from $69.46M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.65$0.87$0.77 - $1.07-25.29%Miss-55.5%4N/ANov 5, 2026$80.89M
    Jun 30, 2026$0.88$0.91-$2.66 - $1.11-3.30%Miss-73.2%40 up, 0 downAug 4, 2026$78.70M
    Mar 31, 2026$0.44$0.87$0.57 - $1.10-49.43%Miss-30.2%30 up, 1 downMay 5, 2026$58.82M
    Dec 31, 2025$1.12$1.20$1.02 - $1.34-6.80%Miss+40.0%52 up, 1 downMar 3, 2026$69.80M
    Sep 30, 2025$1.46$0.94$0.68 - $1.08+55.32%Beat+108.6%51 up, 0 downNov 4, 2025$69.46M
    Jun 30, 2025$3.28$1.41$0.14 - $2.78+132.62%BeatN/A41 up, 0 downAug 5, 2025$101.69M
    Mar 31, 2025$0.63$0.09-$0.08 - $0.37+600.00%BeatN/A50 up, 0 downMay 6, 2025$53.33M
    Dec 31, 2024$0.80$0.58$0.13 - $1.10+38.19%Beat+18947.6%50 up, 0 downMar 4, 2025$57.60M
    Sep 30, 2024$0.70$0.06-$0.21 - $0.32N/AN/AN/A60 up, 0 downNov 7, 2024$55.31M
    Jun 30, 2024-$0.06-$0.18-$0.50 - -$0.13+66.67%BeatN/A50 up, 0 downAug 6, 2024$36.84M
    Mar 31, 2024-$0.50-$0.27-$0.40 - -$0.10-85.19%MissN/A60 up, 0 downMay 7, 2024$29.53M
    Dec 31, 2023$0.00-$0.03-$0.05 - -$0.01+114.00%Beat-58.0%50 up, 0 downMar 5, 2024$35.79M
    Sep 30, 2023-$0.30-$0.66-$0.90 - -$0.60+54.55%BeatN/A60 up, 0 downNov 7, 2023$28.13M
    Jun 30, 2023-$0.40-$0.80-$0.90 - -$0.70+50.00%BeatN/A60 up, 0 downAug 1, 2023$26.89M
    Mar 31, 2023-$0.80-$0.93-$1.20 - -$0.70+13.98%BeatN/A60 up, 0 downMay 2, 2023$26.07M
    Dec 31, 2022$0.01-$0.11-$0.20 - $0.02+109.09%BeatN/A60 up, 0 downMar 7, 2023$51.28M
    Sep 30, 2022-$1.10-$1.36-$1.60 - -$1.20+19.12%BeatN/A71 up, 0 downNov 3, 2022$22.41M
    Jun 30, 2022-$0.80-$1.21-$1.40 - -$1.10+33.88%BeatN/A70 up, 0 downAug 2, 2022$29.82M
    Mar 31, 2022-$1.60-$1.36-$1.80 - -$1.10-17.65%Miss-172.7%70 up, 0 downMay 3, 2022$16.73M
    Dec 31, 2021-$0.13-$0.13-$0.13 - -$0.100.00%In lineN/A6N/AMar 1, 2022$20.41M
    Sep 30, 2021-$1.20-$1.00-$1.30 - -$0.70-20.00%MissN/A6N/ANov 2, 2021$21.54M
    Jun 30, 2021-$0.80-$1.15-$1.30 - -$1.00+30.43%BeatN/A6N/AAug 3, 2021$26.27M
    Mar 31, 2021$2.20$0.30-$1.30 - $2.60+633.33%Beat+1592.3%6N/AMay 5, 2021$81.02M
    Dec 31, 2020-$0.11-$0.11-$0.16 - -$0.090.00%In lineN/A6N/AMar 2, 2021$18.45M
    Sep 30, 2020-$0.80-$1.22-$1.40 - -$1.10+34.43%BeatN/A7N/ANov 5, 2020$18.39M
    Jun 30, 2020-$1.00-$1.33-$1.50 - -$1.20+24.81%BeatN/A7N/AAug 4, 2020$16.02M
    Mar 31, 2020$0.13$0.13$0.12 - $0.140.00%In lineN/A7N/AMay 5, 2020$55.76M
    Dec 31, 2019-$1.00-$0.85-$1.40 - $1.30-17.65%Miss-3433.3%7N/AFeb 27, 2020$15.40M
    Sep 30, 2019-$0.70-$1.07-$1.40 - -$0.70+34.58%BeatN/A7N/ANov 5, 2019$20.86M
    Jun 30, 2019-$1.20-$1.37-$1.50 - -$1.20+12.41%BeatN/A7N/AAug 6, 2019$10.41M
    Mar 31, 2019-$1.10-$1.28-$1.60 - -$1.20+14.06%BeatN/A7N/AMay 7, 2019$12.62M
    Dec 31, 2018$0.03$0.03$0.03 - $0.040.00%In lineN/A7N/AFeb 28, 2019$37.86M
    Sep 30, 2018-$1.40-$1.50-$1.70 - -$1.30+6.67%BeatN/A7N/ANov 6, 2018$4.87M
    Jun 30, 2018-$1.60-$1.62-$1.70 - -$1.60+1.23%BeatN/A6N/AAug 8, 2018$1.79M
    Mar 31, 2018-$1.70-$1.70-$1.80 - -$1.600.00%In lineN/A4N/AMay 1, 2018N/A
    Dec 31, 2017-$0.18-$0.13-$0.14 - -$0.12-38.46%MissN/A6N/AMar 6, 2018$3.58M
    Sep 30, 2017-$1.40-$1.53N/A+8.50%BeatN/A2N/ANov 7, 2017$900000
    Jun 30, 2017-$1.60-$1.50-$1.50 - -$1.40-6.67%MissN/A4N/AAug 1, 2017N/A
    Mar 31, 2017-$1.41-$1.08N/A-30.56%MissN/AN/AN/AMay 2, 2017$3.58M
    Dec 31, 2016-$0.16-$0.17N/A+5.88%BeatN/AN/AN/AMar 7, 2017$3.00M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $6.49, up 590.4% from the year before. It was -$5.36 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$6.49+590.4%
    Dec 31, 2024$0.94N/A
    Dec 31, 2023-$1.50N/A
    Dec 31, 2022-$3.49-5085.7%
    Dec 31, 2021$0.07N/A
    Dec 31, 2020-$1.78N/A
    Dec 31, 2019-$4.00N/A
    Dec 31, 2018-$4.67N/A
    Dec 31, 2017-$4.59N/A
    Dec 31, 2016-$5.36N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,800 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20266,79411
    2026Q2Jun 30, 20266,5259
    2026Q1Mar 31, 20265,31910
    2025Q4Dec 31, 20256,22011
    2025Q3Sep 30, 20254,9989
    2025Q2Jun 30, 20255,4549
    2025Q1Mar 31, 20256,1089
    2024Q4Dec 31, 20247,27011

    2026Q3 Earnings Call

    Opening remarks

    Raymond Furey Executive Vice President, General Counsel and Corporate Secretary Thank you. Welcome to our third quarter 2026 financial results conference call. The financial press release for the third quarter 2026 was issued earlier today and can be viewed along with the slides for this presentation in the News & Events section of our Investor Relations site on rigel.com. As a reminder, during today's call, we may make forward-looking statements regarding our financial outlook and our plans and timing for commercial, regulatory, product development and other business activities. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent annual report on Form 10-K for the year ended December 31, 2025, on file with the SEC, and subsequent filings with the SEC, including our Q3 quarterly report on Form 10-Q with the SEC. Any forward-looking statements are made only as of today's date, and we undertake no obligation to update these forward-looking statements to reflect subsequent events or circumstances except as required by law. At this time, I would like to turn the call over to our President and Chief Executive Officer, Raul Rodriguez. Raul?

    Raul Rodriguez President and Chief Executive Officer Thank you, Ray, and thank you all for joining us today. Also joining me on the call are Dave Santos, our Chief Commercial Officer; Dr. Alison Hannah, our Chief Medical Officer; and Dean Schorno, our Chief Financial Officer. Before we begin, I'd like to share a few key highlights from the quarter. We delivered over $72 million in net product sales, our highest ever, and another profitable quarter. This was while taking important steps towards Rigel's next phase of growth. VEPPANU, Rigel's fourth commercial product, is now available in the U.S. with an encouraging start to its launch, and we continue to advance R289 towards its next stage of development. I'll start with an overview of this progress before the team takes you through the details. Moving to Slide 4. VEPPANU became commercially available in the U.S. on August 13 and generated $6.6 million in net product sales through the end of the third quarter. Following the close of the global in-license agreement in June, our team moved quickly to initiate launch activities, leveraging our established commercial and medical infrastructure to engage physicians and build awareness ahead of commercial availability. Within just 2 months of closing the transaction, VEPPANU was successfully integrated into our existing distribution network and ready for commercial launch. During Q3, we shipped VEPPANU to over 100 patients and clinics. Encouragingly, the majority of the patients who received VEPPANU during the early weeks of launch had already refilled their prescriptions by quarter end.

    Frequently Asked Questions About RIGL

    When is Rigel Pharmaceuticals's next earnings date?

    Rigel Pharmaceuticals's next earnings report is expected for Mar 1, 2027.

    Did RIGL beat earnings estimates last quarter?

    No. Rigel Pharmaceuticals reported EPS of $0.65 for the quarter ended Sep 30, 2026, below the $0.87 estimate by 25.29%.

    What EPS do analysts expect from RIGL next quarter?

    The consensus EPS estimate for Rigel Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.94 from 7 analysts, with estimates from $0.85 to $1.06.

    How often does RIGL beat earnings estimates?

    Rigel Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +92.67%.